Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 + pembrolizumab vs pembrolizumab monotherapy in first-line metastatic NSCLC with high PD-L1
jRCT2051240089Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-2870 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: Overall Survival (OS). Started Jan 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240089.